Name
RF2-01: Prognostic Markers in Residual Tumors after neoadjuvant chemotherapy (NACT) for Early Triple-negative Breast Cancer (TNBC) – a Pooled Analysis from nine Neoadjuvant GBG/AGO-B Trials Commentary by: Joseph Sparano, MD, FACP
Date & Time
Monday, December 1, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL